{"transactions":[{"id":890757,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2026-02-20T22:50:52.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":14305,"price":3.6,"value":51498.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $51,500."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to the underlying shares of Common Stock in 11 equal installments, each on the last day of each remaining month of calendar year 2026."}],"balance_after":14305,"derivative":{"exercise_price":4.45,"expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":14305},"source":{"system":"sec-edgar","filing":"0001739410-26-000015","document":"wk-form4_1771627849.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941026000015/wk-form4_1771627849.xml","form_type":"4"}},{"id":1147445,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2025-05-15T21:08:25.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":28500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders."}],"balance_after":28500,"derivative":{"exercise_price":0.3,"expiration_date":"2035-05-13","underlying":"Common Stock","underlying_shares":28500},"source":{"system":"sec-edgar","filing":"0001739410-25-000085","document":"wk-form4_1747343299.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941025000085/wk-form4_1747343299.xml","form_type":"4"}},{"id":1296267,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"6.500% Exchangeable Senior Subordinated Note due 2025","published_at":"2025-01-23T18:30:04.000Z","date":"2025-01-13","kind":"other","planned":false,"acquired":false,"price":792000,"reported_value":792000,"ownership":{"direct":false,"nature":"By New Leaf Biopharma Opportunities II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 21, 2020, Iterum Therapeutics Bermuda Limited (the \"Issuer\"), a wholly-owned subsidiary of Iterum Therapeutics plc (the \"Company\"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the \"Exchangeable Notes\") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. The Exchangeable Notes were exchangeable into, at the Company's election, ordinary shares, nominal value $0.01 per share of the Company (the \"Ordinary Shares\"), cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 Ordinary Shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share), subject to anti-dilution adjustments as set forth in the indenture governing the Exchangeable Notes."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(Continued from Footnote 1) Subject to the terms of the indenture governing the Exchangeable Notes (the \"Indenture\"), on or after January 21, 2021 until January 13, 2025, the second scheduled trading day immediately preceding January 15, 2025, holders could exchange the Exchangeable Notes (the \"Final Exchange Date\"). The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms."},{"field":"date","element":"transactionDate","label":"F3","text":"In accordance with the terms of the Indenture, the Exchangeable Notes are no longer exchangeable after the Final Exchange Date. The Reporting Person did not sell or dispose of the Exchangeable Notes or the Ordinary Shares underlying the Exchangeable Notes."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 21, 2020, Iterum Therapeutics Bermuda Limited (the \"Issuer\"), a wholly-owned subsidiary of Iterum Therapeutics plc (the \"Company\"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the \"Exchangeable Notes\") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. The Exchangeable Notes were exchangeable into, at the Company's election, ordinary shares, nominal value $0.01 per share of the Company (the \"Ordinary Shares\"), cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 Ordinary Shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share), subject to anti-dilution adjustments as set forth in the indenture governing the Exchangeable Notes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Subject to the terms of the indenture governing the Exchangeable Notes (the \"Indenture\"), on or after January 21, 2021 until January 13, 2025, the second scheduled trading day immediately preceding January 15, 2025, holders could exchange the Exchangeable Notes (the \"Final Exchange Date\"). The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms."},{"field":"kind","element":"transactionCoding","label":"F3","text":"In accordance with the terms of the Indenture, the Exchangeable Notes are no longer exchangeable after the Final Exchange Date. The Reporting Person did not sell or dispose of the Exchangeable Notes or the Ordinary Shares underlying the Exchangeable Notes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 21, 2020, Iterum Therapeutics Bermuda Limited (the \"Issuer\"), a wholly-owned subsidiary of Iterum Therapeutics plc (the \"Company\"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the \"Exchangeable Notes\") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. The Exchangeable Notes were exchangeable into, at the Company's election, ordinary shares, nominal value $0.01 per share of the Company (the \"Ordinary Shares\"), cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 Ordinary Shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share), subject to anti-dilution adjustments as set forth in the indenture governing the Exchangeable Notes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Subject to the terms of the indenture governing the Exchangeable Notes (the \"Indenture\"), on or after January 21, 2021 until January 13, 2025, the second scheduled trading day immediately preceding January 15, 2025, holders could exchange the Exchangeable Notes (the \"Final Exchange Date\"). The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"In accordance with the terms of the Indenture, the Exchangeable Notes are no longer exchangeable after the Final Exchange Date. The Reporting Person did not sell or dispose of the Exchangeable Notes or the Ordinary Shares underlying the Exchangeable Notes."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Represents the amount of Ordinary Shares that were underlying the relevant Exchangeable Note based on the current exchange rate of 546.4481 Ordinary Shares per $1,000 of principal and interest on such Exchangeable Note."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Exchangeable Note is held directly by New Leaf Biopharma Opportunities II, L.P. (\"NBPO-II\"). New Leaf BPO Associates II, L.P. (\"NBPO-IIA\") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. (\"NBPO-IIM\") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-IIM may be deemed to have sole voting, investment and dispositive power with respect to the Exchangeable Note held by NBPO-II. The Reporting Person, a member of the Company's Board of Directors, is a managing director of NBPO-IIM and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the Exchangeable Note held by NBPO-II. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of his pecuniary interest therein, if any."}],"derivative":{"expiration_date":"2025-01-13","underlying":"Ordinary Shares","underlying_shares":432787},"source":{"system":"sec-edgar","filing":"0000950170-25-008443","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017025008443/ownership.xml","form_type":"4"}},{"id":1296266,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"6.500% Exchangeable Senior Subordinated Note due 2025","published_at":"2025-01-23T18:30:04.000Z","date":"2025-01-13","kind":"other","planned":false,"acquired":false,"price":2208000,"reported_value":2208000,"ownership":{"direct":false,"nature":"By New Leaf Ventures III, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 21, 2020, Iterum Therapeutics Bermuda Limited (the \"Issuer\"), a wholly-owned subsidiary of Iterum Therapeutics plc (the \"Company\"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the \"Exchangeable Notes\") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. The Exchangeable Notes were exchangeable into, at the Company's election, ordinary shares, nominal value $0.01 per share of the Company (the \"Ordinary Shares\"), cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 Ordinary Shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share), subject to anti-dilution adjustments as set forth in the indenture governing the Exchangeable Notes."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(Continued from Footnote 1) Subject to the terms of the indenture governing the Exchangeable Notes (the \"Indenture\"), on or after January 21, 2021 until January 13, 2025, the second scheduled trading day immediately preceding January 15, 2025, holders could exchange the Exchangeable Notes (the \"Final Exchange Date\"). The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms."},{"field":"date","element":"transactionDate","label":"F3","text":"In accordance with the terms of the Indenture, the Exchangeable Notes are no longer exchangeable after the Final Exchange Date. The Reporting Person did not sell or dispose of the Exchangeable Notes or the Ordinary Shares underlying the Exchangeable Notes."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 21, 2020, Iterum Therapeutics Bermuda Limited (the \"Issuer\"), a wholly-owned subsidiary of Iterum Therapeutics plc (the \"Company\"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the \"Exchangeable Notes\") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. The Exchangeable Notes were exchangeable into, at the Company's election, ordinary shares, nominal value $0.01 per share of the Company (the \"Ordinary Shares\"), cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 Ordinary Shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share), subject to anti-dilution adjustments as set forth in the indenture governing the Exchangeable Notes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Subject to the terms of the indenture governing the Exchangeable Notes (the \"Indenture\"), on or after January 21, 2021 until January 13, 2025, the second scheduled trading day immediately preceding January 15, 2025, holders could exchange the Exchangeable Notes (the \"Final Exchange Date\"). The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms."},{"field":"kind","element":"transactionCoding","label":"F3","text":"In accordance with the terms of the Indenture, the Exchangeable Notes are no longer exchangeable after the Final Exchange Date. The Reporting Person did not sell or dispose of the Exchangeable Notes or the Ordinary Shares underlying the Exchangeable Notes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 21, 2020, Iterum Therapeutics Bermuda Limited (the \"Issuer\"), a wholly-owned subsidiary of Iterum Therapeutics plc (the \"Company\"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the \"Exchangeable Notes\") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. The Exchangeable Notes were exchangeable into, at the Company's election, ordinary shares, nominal value $0.01 per share of the Company (the \"Ordinary Shares\"), cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 Ordinary Shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share), subject to anti-dilution adjustments as set forth in the indenture governing the Exchangeable Notes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Subject to the terms of the indenture governing the Exchangeable Notes (the \"Indenture\"), on or after January 21, 2021 until January 13, 2025, the second scheduled trading day immediately preceding January 15, 2025, holders could exchange the Exchangeable Notes (the \"Final Exchange Date\"). The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"In accordance with the terms of the Indenture, the Exchangeable Notes are no longer exchangeable after the Final Exchange Date. The Reporting Person did not sell or dispose of the Exchangeable Notes or the Ordinary Shares underlying the Exchangeable Notes."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Represents the amount of Ordinary Shares that were underlying the relevant Exchangeable Note based on the current exchange rate of 546.4481 Ordinary Shares per $1,000 of principal and interest on such Exchangeable Note."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Exchangeable Note is held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). New Leaf Venture Associates III, L.P. (\"NLVA-III LP\") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. (\"NLVM-III LLC\") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the Exchangeable Note held by NLV-III. The Reporting Person, a member of the Company's Board of Directors, is a managing director of NLVM-III LLC and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the Exchangeable Note held by NLV-III. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of his pecuniary interest therein, if any."}],"derivative":{"expiration_date":"2025-01-13","underlying":"Ordinary Shares","underlying_shares":1206557},"source":{"system":"sec-edgar","filing":"0000950170-25-008443","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017025008443/ownership.xml","form_type":"4"}},{"id":1310814,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2025-01-06T22:07:03.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":73571,"price":0.7,"value":51499.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $51,500."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2025."}],"balance_after":73571,"derivative":{"exercise_price":0.95,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":73571},"source":{"system":"sec-edgar","filing":"0001739410-25-000007","document":"wk-form4_1736201216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941025000007/wk-form4_1736201216.xml","form_type":"4"}},{"id":1435849,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2024-08-12T09:00:03.000Z","date":"2024-08-06","kind":"exercise","planned":false,"acquired":true,"shares":65481,"ownership":{"direct":false,"nature":"By New Leaf Biopharma Opportunities II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities were purchased in the Issuer's rights offering (the \"Offering\") which closed on August 9, 2024. As part of the Offering, New Leaf Biopharma Opportunities II, L.P. (\"NBPO-II\") purchased 65,481 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance (\"1-year warrants\"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance (\"5-year warrants\")."}],"balance_after":65481,"derivative":{"exercise_price":1.21,"exercise_date":"2024-08-09","expiration_date":"2029-08-09","underlying":"Ordinary Shares","underlying_shares":65481},"source":{"system":"sec-edgar","filing":"0000950170-24-095094","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024095094/ownership.xml","form_type":"4"}},{"id":1435848,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2024-08-12T09:00:03.000Z","date":"2024-08-06","kind":"exercise","planned":false,"acquired":true,"shares":65481,"ownership":{"direct":false,"nature":"By New Leaf Biopharma Opportunities II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities were purchased in the Issuer's rights offering (the \"Offering\") which closed on August 9, 2024. As part of the Offering, New Leaf Biopharma Opportunities II, L.P. (\"NBPO-II\") purchased 65,481 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance (\"1-year warrants\"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance (\"5-year warrants\")."}],"balance_after":65481,"derivative":{"exercise_price":1.21,"exercise_date":"2024-08-09","expiration_date":"2025-08-09","underlying":"Ordinary Shares","underlying_shares":32740},"source":{"system":"sec-edgar","filing":"0000950170-24-095094","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024095094/ownership.xml","form_type":"4"}},{"id":1435847,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Subscription Rights (right to buy)","published_at":"2024-08-12T09:00:03.000Z","date":"2024-08-06","kind":"exercise","planned":false,"acquired":false,"shares":130962,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By New Leaf Biopharma Opportunities II, L.P."},"footnotes":[{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"NBPO-II validly exercised 130,962 subscription rights to acquire 65,481 units composed of (i) 65,481 ordinary shares, (ii) 65,481 1-year warrants and (iii) 65,481 5-year warrants."}],"balance_after":0,"derivative":{"exercise_price":0.61,"exercise_date":"2024-07-22","expiration_date":"2024-08-06","underlying":"Units"},"source":{"system":"sec-edgar","filing":"0000950170-24-095094","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024095094/ownership.xml","form_type":"4"}},{"id":1435846,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2024-08-12T09:00:03.000Z","date":"2024-08-06","kind":"exercise","planned":false,"acquired":true,"shares":182453,"ownership":{"direct":false,"nature":"By New Leaf Ventures III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased in the Issuer's rights offering (the \"Offering\") which closed on August 9, 2024. As part of the Offering, New Leaf Ventures III, L.P. (\"NLV-III\") purchased 182,453 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance (\"1-year warrants\"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance (\"5-year warrants\")."}],"balance_after":182453,"derivative":{"exercise_price":1.21,"exercise_date":"2024-08-09","expiration_date":"2029-08-09","underlying":"Ordinary Shares","underlying_shares":182453},"source":{"system":"sec-edgar","filing":"0000950170-24-095094","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024095094/ownership.xml","form_type":"4"}},{"id":1435845,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2024-08-12T09:00:03.000Z","date":"2024-08-06","kind":"exercise","planned":false,"acquired":true,"shares":182453,"ownership":{"direct":false,"nature":"By New Leaf Ventures III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased in the Issuer's rights offering (the \"Offering\") which closed on August 9, 2024. As part of the Offering, New Leaf Ventures III, L.P. (\"NLV-III\") purchased 182,453 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance (\"1-year warrants\"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance (\"5-year warrants\")."}],"balance_after":182453,"derivative":{"exercise_price":1.21,"exercise_date":"2024-08-09","expiration_date":"2025-08-09","underlying":"Ordinary Shares","underlying_shares":91226},"source":{"system":"sec-edgar","filing":"0000950170-24-095094","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024095094/ownership.xml","form_type":"4"}},{"id":1435844,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Subscription Rights (right to buy)","published_at":"2024-08-12T09:00:03.000Z","date":"2024-08-06","kind":"exercise","planned":false,"acquired":false,"shares":364906,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By New Leaf Ventures III, L.P."},"footnotes":[{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"NLV-III validly exercised 364,906 subscription rights to acquire 182,453 units composed of (i) 182,453 ordinary shares, (ii) 182,453 1-year warrants and (iii) 182,453 5-year warrants."}],"balance_after":0,"derivative":{"exercise_price":0.61,"exercise_date":"2024-07-22","expiration_date":"2024-08-06","underlying":"Units"},"source":{"system":"sec-edgar","filing":"0000950170-24-095094","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024095094/ownership.xml","form_type":"4"}},{"id":1435843,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-08-12T09:00:03.000Z","date":"2024-08-06","kind":"exercise","planned":false,"acquired":true,"shares":65481,"ownership":{"direct":false,"nature":"By New Leaf Biopharma Opportunities II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities were purchased in the Issuer's rights offering (the \"Offering\") which closed on August 9, 2024. As part of the Offering, New Leaf Biopharma Opportunities II, L.P. (\"NBPO-II\") purchased 65,481 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance (\"1-year warrants\"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance (\"5-year warrants\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by NBPO-II. New Leaf BPO Associates II, L.P. (\"NBPO-IIA\") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. (\"NBPO-IIM\") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-IIM may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NBPO-II. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NBPO-IIM and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NBPO-II. The reporting person disclaims Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":91122,"source":{"system":"sec-edgar","filing":"0000950170-24-095094","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024095094/ownership.xml","form_type":"4"}},{"id":1435842,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-08-12T09:00:03.000Z","date":"2024-08-06","kind":"exercise","planned":false,"acquired":true,"shares":182453,"ownership":{"direct":false,"nature":"By New Leaf Ventures III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased in the Issuer's rights offering (the \"Offering\") which closed on August 9, 2024. As part of the Offering, New Leaf Ventures III, L.P. (\"NLV-III\") purchased 182,453 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance (\"1-year warrants\"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance (\"5-year warrants\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by NLV-III. New Leaf Venture Associates III, L.P. (\"NLVA-III LP\") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. (\"NLVM-III LLC\") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NLVM-III LLC and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The reporting person disclaims Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of his pecuniary interest therein, if any."}],"balance_after":253898,"source":{"system":"sec-edgar","filing":"0000950170-24-095094","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024095094/ownership.xml","form_type":"4"}},{"id":1511527,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2024-05-17T21:06:10.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 15, 2025 or the date of the Company's 2025 Annual Meeting of Stockholders."}],"balance_after":16500,"derivative":{"exercise_price":1.91,"expiration_date":"2034-05-15","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001739410-24-000094","document":"wk-form4_1715979961.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000094/wk-form4_1715979961.xml","form_type":"4"}},{"id":1583868,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-03-11T17:26:33.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time,"},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"(continued from footnote 12) (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"(continued from footnote 12) (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F13","text":"(continued from footnote 12) (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":6.657,"underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0000950170-24-029446","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024029446/ownership.xml","form_type":"4"}},{"id":1583867,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-03-11T17:26:33.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3214,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time,"},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"(continued from footnote 12) (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"(continued from footnote 12) (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F13","text":"(continued from footnote 12) (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":20.1,"underlying":"Common Stock","underlying_shares":3214},"source":{"system":"sec-edgar","filing":"0000950170-24-029446","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024029446/ownership.xml","form_type":"4"}},{"id":1583866,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-03-11T17:26:33.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1016,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time,"},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"(continued from footnote 12) (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"(continued from footnote 12) (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F13","text":"(continued from footnote 12) (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":20.1,"underlying":"Common Stock","underlying_shares":1016},"source":{"system":"sec-edgar","filing":"0000950170-24-029446","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024029446/ownership.xml","form_type":"4"}},{"id":1583865,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-03-11T17:26:33.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2033,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time,"},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"(continued from footnote 12) (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"(continued from footnote 12) (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F13","text":"(continued from footnote 12) (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":21.1453,"underlying":"Common Stock","underlying_shares":2033},"source":{"system":"sec-edgar","filing":"0000950170-24-029446","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024029446/ownership.xml","form_type":"4"}},{"id":1583864,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2024-03-11T17:26:33.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":85750,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof or the parties to the Merger Agreement, each warrant that was outstanding and unexercised immediately prior to the Effective Time, in accordance with its terms, ceased to represent a warrant exercisable for Common Stock and became a warrant exercisable for the Common Stock Merger Consideration that such holder would have been entitled to receive if such warrant had been exercised immediately prior to the Effective Time."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The sole general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The sole general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Reporting Person, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"NLV-III Managers\") are managing directors of Management-III and may be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"exercise_price":5.8345,"exercise_date":"2023-10-25","expiration_date":"2026-10-25","underlying":"Common Stock","underlying_shares":85750},"source":{"system":"sec-edgar","filing":"0000950170-24-029446","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024029446/ownership.xml","form_type":"4"}},{"id":1583863,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2024-03-11T17:26:33.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":686000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof or the parties to the Merger Agreement, each warrant that was outstanding and unexercised immediately prior to the Effective Time, in accordance with its terms, ceased to represent a warrant exercisable for Common Stock and became a warrant exercisable for the Common Stock Merger Consideration that such holder would have been entitled to receive if such warrant had been exercised immediately prior to the Effective Time."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These shares are held directly by New Leaf Biopharma Opportunities II, L.P. (\"BPO-II\"). The sole general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The sole general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The Reporting Person, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"BPO-II Managing Directors\") are managing directors of BPO Management-II and may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"exercise_price":5.8345,"exercise_date":"2023-10-25","expiration_date":"2026-10-25","underlying":"Common Stock","underlying_shares":686000},"source":{"system":"sec-edgar","filing":"0000950170-24-029446","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024029446/ownership.xml","form_type":"4"}},{"id":1583862,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2024-03-11T17:26:33.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":299430,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof or the parties to the Merger Agreement, each warrant that was outstanding and unexercised immediately prior to the Effective Time, in accordance with its terms, ceased to represent a warrant exercisable for Common Stock and became a warrant exercisable for the Common Stock Merger Consideration that such holder would have been entitled to receive if such warrant had been exercised immediately prior to the Effective Time."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These shares are held directly by New Leaf Biopharma Opportunities II, L.P. (\"BPO-II\"). The sole general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The sole general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The Reporting Person, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"BPO-II Managing Directors\") are managing directors of BPO Management-II and may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"exercise_price":9.7889,"exercise_date":"2023-03-23","expiration_date":"2031-03-23","underlying":"Common Stock","underlying_shares":299430},"source":{"system":"sec-edgar","filing":"0000950170-24-029446","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024029446/ownership.xml","form_type":"4"}},{"id":1583861,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"8.000% Series A Redeemable Preferred Stock","published_at":"2024-03-11T17:26:33.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of the Issuer's Series A Redeemable Preferred Stock, par value of $0.0001 per share (\"Series A Preferred Stock\") issued and outstanding was cancelled and the holder thereof was entitled to receive 3,577.77 per share of Series A Preferred Stock in respect of each Series A Preferred Stock determined in accordance with the terms of the Series A Preferred Stock, subject to applicable withholding taxes."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These shares are held directly by New Leaf Biopharma Opportunities II, L.P. (\"BPO-II\"). The sole general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The sole general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The Reporting Person, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"BPO-II Managing Directors\") are managing directors of BPO Management-II and may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-029446","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024029446/ownership.xml","form_type":"4"}},{"id":1583860,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-11T17:26:33.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":395783,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the \"Common Stock Merger Consideration\")."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The sole general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The sole general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The Reporting Person, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"NLV-III Managers\") are managing directors of Management-III and may be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-029446","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024029446/ownership.xml","form_type":"4"}},{"id":1583859,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-11T17:26:33.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1463386,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the \"Common Stock Merger Consideration\")."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These shares are held directly by New Leaf Biopharma Opportunities II, L.P. (\"BPO-II\"). The sole general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The sole general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The Reporting Person, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"BPO-II Managing Directors\") are managing directors of BPO Management-II and may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-029446","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024029446/ownership.xml","form_type":"4"}},{"id":1583858,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-11T17:26:33.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13224,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"Includes 13,224 RSUs which are subject to rounding as a result of the 1:10 reverse stock split effective September 1, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the \"Common Stock Merger Consideration\")."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-029446","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024029446/ownership.xml","form_type":"4"}},{"id":1583857,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-11T17:26:33.000Z","date":"2024-03-08","kind":"grant","planned":false,"acquired":true,"shares":424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") issuable upon the settlement of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock. The fully vested RSUs were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of prorated retainer fees totaling $9,753.00 for the first quarter of 2024."}],"balance_after":13224,"source":{"system":"sec-edgar","filing":"0000950170-24-029446","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024029446/ownership.xml","form_type":"4"}},{"id":1687943,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2024-01-04T22:56:30.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":29096,"price":1.77,"value":51499.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $51,500."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2024."}],"balance_after":29096,"derivative":{"exercise_price":2.4,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":29096},"source":{"system":"sec-edgar","filing":"0001739410-24-000003","document":"wk-form4_1704408977.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000003/wk-form4_1704408977.xml","form_type":"4"}},{"id":1691558,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-03T16:30:44.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":1072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon the settlement of restricted stock units (\"RSUs\"). The fully vested RSUs were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $12,500."}],"balance_after":12801,"source":{"system":"sec-edgar","filing":"0000950170-24-000960","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000095017024000960/ownership.xml","form_type":"4"}},{"id":1728462,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-28T16:25:55.000Z","date":"2023-11-27","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon the settlement of restricted stock units (\"RSUs\"). 25% of the RSUs will vest on each May 27th and November 27th of 2024 and 2025, subject to acceleration and vesting in full upon a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan) of the Issuer, and subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":11729,"source":{"system":"sec-edgar","filing":"0001209191-23-056796","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919123056796/doc4.xml","form_type":"4"}},{"id":1754254,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-10-27T16:03:17.000Z","date":"2023-10-25","kind":"purchase","planned":false,"acquired":true,"shares":85750,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price is also subject to adjustment pursuant to the Common Stock Purchase Warrant issued on October 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of the Issuer's Common Stock and accompanying warrants were purchased in the Issuer's private placement of Common Stock and warrants pursuant to a Securities Purchase Agreement, dated October 22, 2023, by and among the Issuer and the other purchasers named therein. The shares of Common Stock and warrants acquired were purchased at a price representative of $5.8345 per share of Common Stock and accompanying warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The sole general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The sole general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"NLV-III Managers\") are managing directors of Management-III and may be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":85750,"derivative":{"exercise_price":5.8345,"exercise_date":"2023-10-25","expiration_date":"2026-10-25","underlying":"Common Stock","underlying_shares":85750},"source":{"system":"sec-edgar","filing":"0001209191-23-053737","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919123053737/doc4.xml","form_type":"4"}},{"id":1754253,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-10-27T16:03:17.000Z","date":"2023-10-25","kind":"purchase","planned":false,"acquired":true,"shares":686000,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price is also subject to adjustment pursuant to the Common Stock Purchase Warrant issued on October 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of the Issuer's Common Stock and accompanying warrants were purchased in the Issuer's private placement of Common Stock and warrants pursuant to a Securities Purchase Agreement, dated October 22, 2023, by and among the Issuer and the other purchasers named therein. The shares of Common Stock and warrants acquired were purchased at a price representative of $5.8345 per share of Common Stock and accompanying warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Biopharma Opportunities II, L.P. (\"BPO-II\"). The sole general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The sole general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"BPO-II Managing Directors\") are managing directors of BPO Management-II and may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":686000,"derivative":{"exercise_price":5.8345,"exercise_date":"2023-10-25","expiration_date":"2026-10-25","underlying":"Common Stock","underlying_shares":686000},"source":{"system":"sec-edgar","filing":"0001209191-23-053737","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919123053737/doc4.xml","form_type":"4"}},{"id":1754252,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-27T16:03:17.000Z","date":"2023-10-25","kind":"purchase","planned":false,"acquired":true,"shares":171500,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of the Issuer's Common Stock and accompanying warrants were purchased in the Issuer's private placement of Common Stock and warrants pursuant to a Securities Purchase Agreement, dated October 22, 2023, by and among the Issuer and the other purchasers named therein. The shares of Common Stock and warrants acquired were purchased at a price representative of $5.8345 per share of Common Stock and accompanying warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The sole general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The sole general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"NLV-III Managers\") are managing directors of Management-III and may be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":395783,"source":{"system":"sec-edgar","filing":"0001209191-23-053737","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919123053737/doc4.xml","form_type":"4"}},{"id":1754251,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-27T16:03:17.000Z","date":"2023-10-25","kind":"purchase","planned":false,"acquired":true,"shares":1372000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of the Issuer's Common Stock and accompanying warrants were purchased in the Issuer's private placement of Common Stock and warrants pursuant to a Securities Purchase Agreement, dated October 22, 2023, by and among the Issuer and the other purchasers named therein. The shares of Common Stock and warrants acquired were purchased at a price representative of $5.8345 per share of Common Stock and accompanying warrant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Biopharma Opportunities II, L.P. (\"BPO-II\"). The sole general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The sole general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a board member of the Issuer, and Vijay K. Lathi (collectively, the \"BPO-II Managing Directors\") are managing directors of BPO Management-II and may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1463386,"source":{"system":"sec-edgar","filing":"0001209191-23-053737","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919123053737/doc4.xml","form_type":"4"}},{"id":1770257,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-02T17:35:55.000Z","date":"2023-10-01","kind":"grant","planned":false,"acquired":true,"shares":3035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon the settlement of restricted stock units (\"RSUs\").  The fully vested RSUs were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $12,500."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Shares reflect 1:10 reverse stock split effective September 1, 2023."}],"balance_after":6729,"source":{"system":"sec-edgar","filing":"0001209191-23-051149","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919123051149/doc4.xml","form_type":"4"}},{"id":1770256,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2023-10-02T09:22:25.000Z","date":"2023-10-01","kind":"exercise","planned":false,"acquired":false,"shares":5479,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted share units (\"RSUs\") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On December 23, 2022, the reporting person was granted an award of 5,479 RSUs, which vested in full on October 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On December 23, 2022, the reporting person was granted an award of 5,479 RSUs, which vested in full on October 1, 2023."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5479},"source":{"system":"sec-edgar","filing":"0001209191-23-050912","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919123050912/doc4.xml","form_type":"4"}},{"id":1770255,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-10-02T09:22:25.000Z","date":"2023-10-01","kind":"exercise","planned":false,"acquired":true,"shares":5479,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted share units (\"RSUs\") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs."}],"balance_after":14346,"source":{"system":"sec-edgar","filing":"0001209191-23-050912","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919123050912/doc4.xml","form_type":"4"}},{"id":1833620,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-06T18:36:30.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":18656,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon the settlement of restricted stock units (\"RSUs\").  The fully vested RSUs were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $12,500."}],"balance_after":36941,"source":{"system":"sec-edgar","filing":"0001209191-23-041671","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919123041671/doc4.xml","form_type":"4"}},{"id":1839487,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2023-07-03T08:00:06.000Z","date":"2023-07-01","kind":"exercise","planned":false,"acquired":false,"shares":2796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted share units (\"RSUs\") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On September 25, 2022, the reporting person was granted an award of 2,796 RSUs, which vested in full on July 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On September 25, 2022, the reporting person was granted an award of 2,796 RSUs, which vested in full on July 1, 2023."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":2796},"source":{"system":"sec-edgar","filing":"0001209191-23-040405","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919123040405/doc4.xml","form_type":"4"}},{"id":1839486,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-07-03T08:00:06.000Z","date":"2023-07-01","kind":"exercise","planned":false,"acquired":true,"shares":2796,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted share units (\"RSUs\") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs."}],"balance_after":8867,"source":{"system":"sec-edgar","filing":"0001209191-23-040405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919123040405/doc4.xml","form_type":"4"}},{"id":1845043,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-06-23T16:34:23.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on June 21, 2024, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":23000,"derivative":{"exercise_price":0.6657,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001209191-23-039413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919123039413/doc4.xml","form_type":"4"}},{"id":1884730,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2023-05-19T21:22:07.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":15490,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted under the Company's 2021 Equity Incentive Plan.  The option vests on the earlier of May 17, 2024 or the date of the Company's 2024 Annual Meeting of Stockholders."}],"balance_after":15490,"derivative":{"exercise_price":5.64,"expiration_date":"2033-05-17","underlying":"Common Stock","underlying_shares":15490},"source":{"system":"sec-edgar","filing":"0000899243-23-013396","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924323013396/doc4.xml","form_type":"4"}},{"id":1927413,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-04T17:05:16.000Z","date":"2023-04-01","kind":"grant","planned":false,"acquired":true,"shares":18285,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issuable upon the settlement of restricted stock units (\"RSUs\").  The fully vested RSUs were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $12,500."}],"balance_after":18285,"source":{"system":"sec-edgar","filing":"0001209191-23-022802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919123022802/doc4.xml","form_type":"4"}},{"id":1932112,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2023-04-03T20:00:19.000Z","date":"2023-04-01","kind":"exercise","planned":false,"acquired":false,"shares":2041,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted share units (\"RSUs\") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 25, 2022, the reporting person was granted an award of 2,041 RSUs, which vested in full on April 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 25, 2022, the reporting person was granted an award of 2,041 RSUs, which vested in full on April 1, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the \"Reverse Share Split\").  The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":2041},"source":{"system":"sec-edgar","filing":"0001209191-23-022424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919123022424/doc4.xml","form_type":"4"}},{"id":1932111,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-04-03T20:00:19.000Z","date":"2023-04-01","kind":"exercise","planned":false,"acquired":true,"shares":2041,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted share units (\"RSUs\") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs."}],"balance_after":6071,"source":{"system":"sec-edgar","filing":"0001209191-23-022424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919123022424/doc4.xml","form_type":"4"}},{"id":1937796,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-03-27T17:37:00.000Z","date":"2023-03-23","kind":"purchase","planned":false,"acquired":true,"shares":2994305,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of the Issuer's non-convertible, non-voting 8.000% Series A Redeemable Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), were purchased by New Leaf Biopharma Opportunities II, L.P. (\"BPO-II\") in the Issuer's private placement of Series A Preferred Stock and warrants and pursuant to a Securities Purchase Agreement, dated March 22, 2023, by and among the Issuer, BPO-II and the other purchasers named therein. The terms of the Series A Preferred Stock are set forth in the Certificate of Designation filed as Exhibit 3.1 to the Issuer's Form 8-K filed with the Securities and Exchange Commission on March 27, 2023. The shares of Series A Preferred Stock and Warrants acquired by BPO-II were purchased at a price representative of $1,000 per share for the Series A Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by BPO-II. The sole general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The sole general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a board member of the Issuer, and Vijay K. Lathi (the \"BPO-II Managing Directors\") are managing directors of BPO Management-II and may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2994305,"derivative":{"exercise_price":0.9789,"exercise_date":"2023-03-23","expiration_date":"2031-03-23","underlying":"Common Stock","underlying_shares":2994305},"source":{"system":"sec-edgar","filing":"0000899243-23-009741","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000089924323009741/doc4.xml","form_type":"4"}},{"id":1937795,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"8.000% Series A Redeemable Preferred Stock","published_at":"2023-03-27T17:37:00.000Z","date":"2023-03-23","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1000,"value":10000000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares of the Issuer's non-convertible, non-voting 8.000% Series A Redeemable Preferred Stock, par value $0.0001 per share (the \"Series A Preferred Stock\"), were purchased by New Leaf Biopharma Opportunities II, L.P. (\"BPO-II\") in the Issuer's private placement of Series A Preferred Stock and warrants and pursuant to a Securities Purchase Agreement, dated March 22, 2023, by and among the Issuer, BPO-II and the other purchasers named therein. The terms of the Series A Preferred Stock are set forth in the Certificate of Designation filed as Exhibit 3.1 to the Issuer's Form 8-K filed with the Securities and Exchange Commission on March 27, 2023. The shares of Series A Preferred Stock and Warrants acquired by BPO-II were purchased at a price representative of $1,000 per share for the Series A Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by BPO-II. The sole general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The sole general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a board member of the Issuer, and Vijay K. Lathi (the \"BPO-II Managing Directors\") are managing directors of BPO Management-II and may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000899243-23-009741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000089924323009741/doc4.xml","form_type":"4"}},{"id":2062868,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2023-01-05T23:25:36.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":11099,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2023."}],"balance_after":11099,"derivative":{"exercise_price":6.19,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":11099},"source":{"system":"sec-edgar","filing":"0000899243-23-001044","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924323001044/doc4.xml","form_type":"4"}},{"id":2066512,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2023-01-04T18:00:18.000Z","date":"2023-01-01","kind":"exercise","acquired":false,"shares":1197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted share units (\"RSUs\") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 25, 2022, the reporting person was granted an award of 17,955 RSUs (the \"RSU Grant\"), which vested on January 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 25, 2022, the reporting person was granted an award of 17,955 RSUs (the \"RSU Grant\"), which vested on January 1, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"The number of ordinary shares underlying the RSU Grant have been adjusted to reflect the Reverse Share Split."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Ordinary Shares","underlying_shares":1197},"source":{"system":"sec-edgar","filing":"0001209191-23-001286","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919123001286/doc4.xml","form_type":"4"}},{"id":2066511,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-01-04T18:00:18.000Z","date":"2023-01-01","kind":"exercise","acquired":true,"shares":1197,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted share units (\"RSUs\") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the \"Reverse Share Split\"). The number of ordinary shares reported on this Form 4 have been adjusted to reflect the Reverse Share Split."}],"balance_after":4030,"source":{"system":"sec-edgar","filing":"0001209191-23-001286","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919123001286/doc4.xml","form_type":"4"}},{"id":2075462,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2022-12-28T21:00:15.000Z","date":"2022-12-23","kind":"grant","acquired":true,"shares":5479,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit (\"RSU\") represents the contingent right to receive one ordinary share upon vesting of the RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on October 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on October 1, 2023."}],"balance_after":5479,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5479},"source":{"system":"sec-edgar","filing":"0001209191-22-062872","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919122062872/doc4.xml","form_type":"4"}},{"id":2150433,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2022-09-27T21:00:28.000Z","date":"2022-09-25","kind":"grant","acquired":true,"shares":2796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit (\"RSU\") represents the contingent right to receive one ordinary share upon vesting of the RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated 2018 Equity Incentive Plan, as amended, the RSUs shall vest in full on July 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated 2018 Equity Incentive Plan, as amended, the RSUs shall vest in full on July 1, 2023."}],"balance_after":2796,"derivative":{"underlying":"Ordinary Shares","underlying_shares":2796},"source":{"system":"sec-edgar","filing":"0001209191-22-051415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919122051415/doc4.xml","form_type":"4"}},{"id":2220064,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2022-06-28T21:00:18.000Z","date":"2022-06-25","kind":"grant","acquired":true,"shares":30623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit (\"RSU\") represents the contingent right to receive one ordinary share upon vesting of the RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on April 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on April 1, 2023."}],"balance_after":30623,"derivative":{"underlying":"Ordinary Shares","underlying_shares":30623},"source":{"system":"sec-edgar","filing":"0001209191-22-039707","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919122039707/doc4.xml","form_type":"4"}},{"id":2221903,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-06-24T18:46:46.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":32142,"price":1.4,"value":44998.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $45,000 (\"Election Option\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $45,000 (\"Election Option\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-half of the Election Option vested and became exercisable on June 22, 2022, and 25% of each Election Option will vest and become exercisable on each of September 30, 2022 and December 31, 2022, subject to the continuous service of the Reporting Person with the Issuer through each vesting date."}],"balance_after":32142,"derivative":{"exercise_price":2.01,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":32142},"source":{"system":"sec-edgar","filing":"0001209191-22-039326","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919122039326/doc4.xml","form_type":"4"}},{"id":2221902,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-06-24T18:46:46.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on June 21, 2023, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":10167,"derivative":{"exercise_price":2.01,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-22-039326","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919122039326/doc4.xml","form_type":"4"}},{"id":2221900,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2022-06-24T18:00:31.000Z","date":"2022-06-23","kind":"exercise","acquired":false,"shares":36798,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted share units (\"RSUs\") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On June 23, 2021, the reporting person was granted an award of 36,798 RSUs, which vested on June 23, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On June 23, 2021, the reporting person was granted an award of 36,798 RSUs, which vested on June 23, 2022."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Ordinary Shares","underlying_shares":36798},"source":{"system":"sec-edgar","filing":"0001209191-22-039314","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919122039314/doc4.xml","form_type":"4"}},{"id":2221899,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-06-24T18:00:31.000Z","date":"2022-06-23","kind":"exercise","acquired":true,"shares":36798,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted share units (\"RSUs\") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs."}],"balance_after":42501,"source":{"system":"sec-edgar","filing":"0001209191-22-039314","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919122039314/doc4.xml","form_type":"4"}},{"id":2227317,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2022-06-17T17:00:48.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":647059,"price":0.01,"value":6470.59,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated 2018 Equity Incentive Plan, as amended, the shares subject to this option shall vest in full on June 15, 2023"}],"balance_after":647059,"derivative":{"exercise_price":0.21,"expiration_date":"2032-06-14","underlying":"Ordinary Shares","underlying_shares":647059},"source":{"system":"sec-edgar","filing":"0001209191-22-037939","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919122037939/doc4.xml","form_type":"4"}},{"id":2255332,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2022-05-27T00:11:01.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":13440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted under the Company's 2021 Equity Incentive Plan.  The option vests on the earlier of May 24, 2023 or the date of the Company's 2023 Annual Meeting of Stockholders."}],"balance_after":13440,"derivative":{"exercise_price":12.75,"expiration_date":"2032-05-24","underlying":"Common Stock","underlying_shares":13440},"source":{"system":"sec-edgar","filing":"0000899243-22-019832","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322019832/doc4.xml","form_type":"4"}},{"id":2315112,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2022-03-29T20:00:20.000Z","date":"2022-03-25","kind":"grant","acquired":true,"shares":17955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit (\"RSU\") represents the contingent right to receive one ordinary share upon vesting of the RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on January 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on January 1, 2023."}],"balance_after":17955,"derivative":{"underlying":"Ordinary Shares","underlying_shares":17955},"source":{"system":"sec-edgar","filing":"0001209191-22-021544","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919122021544/doc4.xml","form_type":"4"}},{"id":2444199,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2022-01-06T01:41:07.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":6242,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2022."}],"balance_after":6242,"derivative":{"exercise_price":10.38,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":6242},"source":{"system":"sec-edgar","filing":"0000899243-22-001060","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924322001060/doc4.xml","form_type":"4"}},{"id":2605213,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-12T16:15:00.000Z","date":"2021-01-11","kind":"purchase","acquired":true,"shares":235294,"price":17,"value":3999998.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities II, L.P. (\"BPO-II\"). The general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Person, a member of the Issuer's board of directors, and Vijay K. Lathi are the managers of BPO Management-II (the \"BPO-II Managers\") and may be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":913860,"source":{"system":"sec-edgar","filing":"0000899243-21-032747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000089924321032747/doc4.xml","form_type":"4"}},{"id":2614972,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2021-08-04T21:51:10.000Z","date":"2021-07-28","kind":"grant","acquired":true,"shares":13440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests as to the underlying shares of Common Stock on the earlier of July 28, 2022 and the date of the first annual meeting of stockholders of the Issuer following the closing of its initial public offering. The option expires on July 28, 2031."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The option vests as to the underlying shares of Common Stock on the earlier of July 28, 2022 and the date of the first annual meeting of stockholders of the Issuer following the closing of its initial public offering. The option expires on July 28, 2031."}],"balance_after":13440,"derivative":{"exercise_price":13,"underlying":"Common Stock","underlying_shares":13440},"source":{"system":"sec-edgar","filing":"0000899243-21-031634","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924321031634/doc4.xml","form_type":"4"}},{"id":2614971,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Units","published_at":"2021-08-04T21:51:10.000Z","date":"2021-07-28","kind":"other","acquired":false,"shares":2157838,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the \"Preferred Units\") reported herein were preferred units of Rallybio Holdings, LLC.  The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the \"Preferred Units\") reported herein were preferred units of Rallybio Holdings, LLC.  The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the \"Preferred Units\") reported herein were preferred units of Rallybio Holdings, LLC.  The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the \"Preferred Units\") reported herein were preferred units of Rallybio Holdings, LLC.  The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the \"Preferred Units\") reported herein were preferred units of Rallybio Holdings, LLC.  The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Prior to the effectiveness of the Plan of Liquidation, the Preferred Units of Rallybio Holdings, LLC were convertible into shares of common units of Rallybio Holdings, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are directly held by New Leaf Ventures III, L.P. (\"NLV-III\"). New Leaf Venture Associates III, L.P. (\"NLVA-III LP\") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. (\"NLVM-III LLC) is the general partner of NLVA-III LP. The Reporting Person is a managing director of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Reporting Person disclaims beneficial ownership of the shares held by NLV-III, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":338878},"source":{"system":"sec-edgar","filing":"0000899243-21-031634","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924321031634/doc4.xml","form_type":"4"}},{"id":2614970,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Preferred Units","published_at":"2021-08-04T21:51:10.000Z","date":"2021-07-28","kind":"other","acquired":false,"shares":8742654,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the \"Preferred Units\") reported herein were preferred units of Rallybio Holdings, LLC.  The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the \"Preferred Units\") reported herein were preferred units of Rallybio Holdings, LLC.  The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the \"Preferred Units\") reported herein were preferred units of Rallybio Holdings, LLC.  The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the \"Preferred Units\") reported herein were preferred units of Rallybio Holdings, LLC.  The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the \"Preferred Units\") reported herein were preferred units of Rallybio Holdings, LLC.  The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Prior to the effectiveness of the Plan of Liquidation, the Preferred Units of Rallybio Holdings, LLC were convertible into shares of common units of Rallybio Holdings, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are directly held by New Leaf Ventures III, L.P. (\"NLV-III\"). New Leaf Venture Associates III, L.P. (\"NLVA-III LP\") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. (\"NLVM-III LLC) is the general partner of NLVA-III LP. The Reporting Person is a managing director of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Reporting Person disclaims beneficial ownership of the shares held by NLV-III, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1372989},"source":{"system":"sec-edgar","filing":"0000899243-21-031634","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924321031634/doc4.xml","form_type":"4"}},{"id":2614969,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Preferred Units","published_at":"2021-08-04T21:51:10.000Z","date":"2021-07-28","kind":"other","acquired":false,"shares":1795946,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the \"Preferred Units\") reported herein were preferred units of Rallybio Holdings, LLC.  The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the \"Preferred Units\") reported herein were preferred units of Rallybio Holdings, LLC.  The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the \"Preferred Units\") reported herein were preferred units of Rallybio Holdings, LLC.  The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the \"Preferred Units\") reported herein were preferred units of Rallybio Holdings, LLC.  The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the \"Preferred Units\") reported herein were preferred units of Rallybio Holdings, LLC.  The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Prior to the effectiveness of the Plan of Liquidation, the Preferred Units of Rallybio Holdings, LLC were convertible into shares of common units of Rallybio Holdings, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are directly held by New Leaf Ventures III, L.P. (\"NLV-III\"). New Leaf Venture Associates III, L.P. (\"NLVA-III LP\") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. (\"NLVM-III LLC) is the general partner of NLVA-III LP. The Reporting Person is a managing director of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Reporting Person disclaims beneficial ownership of the shares held by NLV-III, except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":282044},"source":{"system":"sec-edgar","filing":"0000899243-21-031634","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924321031634/doc4.xml","form_type":"4"}},{"id":2614968,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-04T21:51:10.000Z","date":"2021-08-02","kind":"purchase","acquired":true,"shares":153846,"price":13,"value":1999998.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are directly held by New Leaf Biopharma Opportunities II, L.P. (\"NL BPO-II\"). New Leaf BPO Associates II, L.P. (\"NL BPOA-II LP\") is the general partner of NL BPO-II and New Leaf BPO Management II, L.L.C. (\"NL BPOA-II LLC) is the general partner of NL BPOA-II LP.  The Reporting Person is a managing director of NL BPOA-II LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NL BPO-II. The Reporting Person disclaims beneficial ownership of the shares held by NL BPO-II, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2301603,"source":{"system":"sec-edgar","filing":"0000899243-21-031634","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924321031634/doc4.xml","form_type":"4"}},{"id":2614967,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-04T21:51:10.000Z","date":"2021-08-02","kind":"purchase","acquired":true,"shares":153846,"price":13,"value":1999998.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are directly held by New Leaf Ventures III, L.P. (\"NLV-III\"). New Leaf Venture Associates III, L.P. (\"NLVA-III LP\") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. (\"NLVM-III LLC) is the general partner of NLVA-III LP. The Reporting Person is a managing director of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Reporting Person disclaims beneficial ownership of the shares held by NLV-III, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2147757,"source":{"system":"sec-edgar","filing":"0000899243-21-031634","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924321031634/doc4.xml","form_type":"4"}},{"id":2614966,"issuer":{"id":6838,"kind":"organization","name":"Rallybio Corp","symbol":"RLYB"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-04T21:51:10.000Z","date":"2021-07-28","kind":"other","acquired":true,"shares":1993911,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the \"Preferred Units\") reported herein were preferred units of Rallybio Holdings, LLC.  The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively, the \"Preferred Units\") reported herein were preferred units of Rallybio Holdings, LLC.  The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the \"Plan of Liquidation\"). Pursuant to the Plan of Liquidation, the holders of Preferred Units received approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Preferred Units had no expiration date prior to the liquidation."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are directly held by New Leaf Ventures III, L.P. (\"NLV-III\"). New Leaf Venture Associates III, L.P. (\"NLVA-III LP\") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. (\"NLVM-III LLC) is the general partner of NLVA-III LP. The Reporting Person is a managing director of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Reporting Person disclaims beneficial ownership of the shares held by NLV-III, except to the extent of his pecuniary interest therein, if any."}],"balance_after":1993911,"source":{"system":"sec-edgar","filing":"0000899243-21-031634","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1739410/000089924321031634/doc4.xml","form_type":"4"}},{"id":2654610,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-25T16:05:32.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":36798,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one ordinary share upon vesting of the RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Equity Incentive Plan, as amended, the RSUs shall vest in full on June 23, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Equity Incentive Plan, as amended, the RSUs shall vest in full on June 23, 2022."}],"balance_after":36798,"derivative":{"underlying":"Ordinary Shares","underlying_shares":36798},"source":{"system":"sec-edgar","filing":"0000899243-21-025954","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000089924321025954/doc4.xml","form_type":"4"}},{"id":2712103,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-05-14T20:01:15.000Z","date":"2021-05-04","kind":"grant","acquired":true,"shares":4658,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"This option was erroneously reported with a price of $22.50 on the original Form 4 filed on May 7, 2021 due to an administrative error related to the calculation date of the Black-Scholes value."},{"field":"shares","element":"transactionShares","label":"F4","text":"The number of shares underlying the option was erroneously reported as 4,807 on the original Form 4 filed on May 7, 2021 due to an administrative error related to the calculation date of the Black-Scholes value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"50% of the shares subject to the option are fully vested and exercisable, and 25% will vest and become exercisable on September 30, 2021 and December 31, 2021, subject to the continuous service of the Reporting Person on each vesting date."}],"balance_after":4658,"derivative":{"exercise_price":23.2,"expiration_date":"2031-05-03","underlying":"Common Stock","underlying_shares":4658},"source":{"system":"sec-edgar","filing":"0001209191-21-032954","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919121032954/doc4a.xml","form_type":"4/A","original_submission_date":"2021-05-07"}},{"id":2712102,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-05-14T20:01:15.000Z","date":"2021-05-04","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This option was erroneously reported with a price of $22.50 on the original Form 4 filed on May 7, 2021 due to an administrative error."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will fully vest and become exercisable on May 3, 2022, subject to the continuous service of the Reporting Person with the Issuer on such date. The original Form 4 filed on May 7, 2021 erroneously reported this vesting date as May 4, 2022."}],"balance_after":10167,"derivative":{"exercise_price":23.2,"expiration_date":"2031-05-03","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-21-032954","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919121032954/doc4a.xml","form_type":"4/A","original_submission_date":"2021-05-07"}},{"id":2722771,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-05-07T21:54:30.000Z","date":"2021-05-04","kind":"grant","acquired":true,"shares":4807,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"50% of the shares subject to the option are fully vested and exercisable, and 25% will vest and become exercisable on September 30, 2021 and December 31, 2021, subject to the continuous service of the Reporting Person on each vesting date."}],"balance_after":4807,"derivative":{"exercise_price":22.5,"expiration_date":"2031-05-03","underlying":"Common Stock","underlying_shares":4807},"source":{"system":"sec-edgar","filing":"0001209191-21-031105","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919121031105/doc4.xml","form_type":"4"}},{"id":2722770,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-05-07T21:54:30.000Z","date":"2021-05-04","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on May 4, 2022, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":10167,"derivative":{"exercise_price":22.5,"expiration_date":"2031-05-03","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-21-031105","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919121031105/doc4.xml","form_type":"4"}},{"id":3091291,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-07-02T17:50:38.000Z","date":"2020-07-01","kind":"exercise","acquired":false,"shares":5703,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units converted into ordinary shares on a one-for-one basis upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On June 13, 2019, the reporting person was granted an award of 5,703 restricted stock units, which vested on July 1, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On June 13, 2019, the reporting person was granted an award of 5,703 restricted stock units, which vested on July 1, 2020."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5703},"source":{"system":"sec-edgar","filing":"0000899243-20-018337","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000089924320018337/doc4.xml","form_type":"4"}},{"id":3091290,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-07-02T17:50:38.000Z","date":"2020-07-01","kind":"exercise","acquired":true,"shares":5703,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units converted into ordinary shares on a one-for-one basis upon vesting of the units."}],"balance_after":5703,"source":{"system":"sec-edgar","filing":"0000899243-20-018337","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000089924320018337/doc4.xml","form_type":"4"}},{"id":3128885,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-06-01T21:45:27.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":4906,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the last day of each calendar quarter following the grant date of May 28, 2020 (on June 30, 2020, September 30, 2020, December 31, 2020, and March 31, 2021), subject to the continuous service of the Reporting Person on each vesting date."}],"balance_after":4906,"derivative":{"exercise_price":20.59,"expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":4906},"source":{"system":"sec-edgar","filing":"0001209191-20-033321","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919120033321/doc4.xml","form_type":"4"}},{"id":3128884,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-06-01T21:45:27.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on May 28, 2021, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":10167,"derivative":{"exercise_price":20.59,"expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-20-033321","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919120033321/doc4.xml","form_type":"4"}},{"id":3303875,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"6.500% Exchangeable Senior Subordinated Note due 2025","published_at":"2020-01-23T16:58:29.000Z","date":"2020-01-21","kind":"grant","acquired":true,"price":792000,"reported_value":792000,"ownership":{"direct":false,"nature":"By New Leaf Biopharma Opportunities II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 21, 2020, Iterum Therapeutics Bermuda Limited (the \"Issuer\"), a wholly-owned subsidiary of Iterum Therapeutics plc (the \"Company\"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the \"Exchangeable Notes\") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share), subject to anti-dilution adjustments as set forth in the indenture governing the Exchangeable Notes."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(Continued from Footnote 1) Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time.  The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 21, 2020, Iterum Therapeutics Bermuda Limited (the \"Issuer\"), a wholly-owned subsidiary of Iterum Therapeutics plc (the \"Company\"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the \"Exchangeable Notes\") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share), subject to anti-dilution adjustments as set forth in the indenture governing the Exchangeable Notes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time.  The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Exchangeable Note is held directly by New Leaf Biopharma Opportunities II, L.P. (\"NBPO-II\"). New Leaf BPO Associates II, L.P. (\"NBPO-IIA\") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. (\"NBPO-IIM\") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-IIM may be deemed to have sole voting, investment and dispositive power with respect to the Exchangeable Note held by NBPO-II. The Reporting Person, a member of the Company's Board of Directors, is a managing director of NBPO-IIM and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the Exchangeable Note held by NBPO-II. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of his pecuniary interest therein, if any."}],"derivative":{"expiration_date":"2025-01-31","underlying":"Ordinary Shares","underlying_shares":792000},"source":{"system":"sec-edgar","filing":"0000899243-20-001845","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000089924320001845/doc4.xml","form_type":"4"}},{"id":3303874,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"6.500% Exchangeable Senior Subordinated Note due 2025","published_at":"2020-01-23T16:58:29.000Z","date":"2020-01-21","kind":"grant","acquired":true,"price":2208000,"reported_value":2208000,"ownership":{"direct":false,"nature":"By New Leaf Ventures III, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 21, 2020, Iterum Therapeutics Bermuda Limited (the \"Issuer\"), a wholly-owned subsidiary of Iterum Therapeutics plc (the \"Company\"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the \"Exchangeable Notes\") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share), subject to anti-dilution adjustments as set forth in the indenture governing the Exchangeable Notes."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(Continued from Footnote 1) Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time.  The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 21, 2020, Iterum Therapeutics Bermuda Limited (the \"Issuer\"), a wholly-owned subsidiary of Iterum Therapeutics plc (the \"Company\"), issued and sold, among other things, 6.500% exchangeable senior subordinated notes due 2025 (the \"Exchangeable Notes\") pursuant to a securities purchase agreement among the Issuer, the Company, the Company's wholly-owned subsidiaries and a group of accredited investors. The Exchangeable Notes are exchangeable into, at the Company's election, Ordinary Shares of the Company, cash or a combination of Ordinary Shares and cash, at an initial exchange rate of 1,000 shares per $1,000 principal amount of Exchangeable Notes (equivalent to an initial exchange price of approximately $1.00 per Ordinary Share), subject to anti-dilution adjustments as set forth in the indenture governing the Exchangeable Notes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) Subject to the terms of the indenture governing the Exchangeable Notes, on or after January 21, 2021 until the second scheduled trading day immediately preceding January 15, 2025, holders may exchange the Exchangeable Notes at any time.  The Exchangeable Notes mature on January 31, 2025, unless earlier exchanged, redeemed or repurchased in accordance with their terms."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Exchangeable Note is held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). New Leaf Venture Associates III, L.P. (\"NLVA-III LP\") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. (\"NLVM-III LLC\") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the Exchangeable Note held by NLV-III. The Reporting Person, a member of the Company's Board of Directors, is a managing director of NLVM-III LLC and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the Exchangeable Note held by NLV-III. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of his pecuniary interest therein, if any."}],"derivative":{"expiration_date":"2025-01-31","underlying":"Ordinary Shares","underlying_shares":2208000},"source":{"system":"sec-edgar","filing":"0000899243-20-001845","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000089924320001845/doc4.xml","form_type":"4"}},{"id":3487509,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-17T17:01:54.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":5703,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one ordinary share upon vesting of the RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Equity Incentive Plan, the RSUs shall vest on June 13, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Equity Incentive Plan, the RSUs shall vest on June 13, 2020."}],"balance_after":5703,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5703},"source":{"system":"sec-edgar","filing":"0000899243-19-017204","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000089924319017204/doc4.xml","form_type":"4"}},{"id":3500289,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2019-06-05T17:27:54.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on June 3, 2020, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":10167,"derivative":{"exercise_price":11.84,"expiration_date":"2029-06-02","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-19-034847","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919119034847/doc4.xml","form_type":"4"}},{"id":3564205,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T17:31:41.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":847,"price":14.75,"value":12493.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Issuer's non-employee directors compensation plan the Reporting Person elected to receive shares of the Issuer's Common Stock in lieu of a cash retainer."}],"balance_after":847,"source":{"system":"sec-edgar","filing":"0001209191-19-023352","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919119023352/doc4.xml","form_type":"4"}},{"id":3573904,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2019-03-29T16:28:22.000Z","date":"2019-02-07","kind":"grant","acquired":true,"shares":4923,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option, which was granted on February 7, 2019, was omitted from the Reporting Person's original Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the last day of each calendar quarter following the grant date of February 7, 2019 (on March 31, 2019, June 30, 2019, September 30, 2019, and December 31, 2019), subject to the continuous service of the Reporting Person on each vesting date."}],"balance_after":4923,"derivative":{"exercise_price":14,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":4923},"source":{"system":"sec-edgar","filing":"0001209191-19-021751","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919119021751/doc4a.xml","form_type":"4/A","original_submission_date":"2019-02-14"}},{"id":3656216,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2019-02-14T17:30:01.000Z","date":"2019-02-12","kind":"exercise","acquired":false,"shares":464281,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities II, L.P. (\"BPO-II\"). The general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Ronald M. Hunt, Vijay K. Lathi, Liam T. Ratcliffe and Isaac A. Manke, the managers of BPO Management-II (the \"BPO-II Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":464281},"source":{"system":"sec-edgar","filing":"0001209191-19-010306","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919119010306/doc4.xml","form_type":"4"}},{"id":3656215,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2019-02-14T17:30:01.000Z","date":"2019-02-12","kind":"exercise","acquired":false,"shares":464281,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, a member of the Issuer's board of directors, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-III (the \"NLV-III Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":464281},"source":{"system":"sec-edgar","filing":"0001209191-19-010306","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919119010306/doc4.xml","form_type":"4"}},{"id":3656214,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2019-02-14T17:30:01.000Z","date":"2019-02-12","kind":"exercise","acquired":false,"shares":1564272,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, a member of the Issuer's board of directors, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-III (the \"NLV-III Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1564272},"source":{"system":"sec-edgar","filing":"0001209191-19-010306","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919119010306/doc4.xml","form_type":"4"}},{"id":3656213,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2019-02-14T17:30:01.000Z","date":"2018-12-19","kind":"grant","acquired":true,"shares":20335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Reflects a transaction with the Issuer prior to its Section 12 registration which occurred within 6 months of the post-registration transaction reported on this Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests in three annual installments starting on December 19, 2019, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":20335,"derivative":{"exercise_price":2.12,"expiration_date":"2028-12-19","underlying":"Common Stock","underlying_shares":20335},"source":{"system":"sec-edgar","filing":"0001209191-19-010306","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919119010306/doc4.xml","form_type":"4"}},{"id":3656212,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2019-02-14T17:30:01.000Z","date":"2018-11-09","kind":"purchase","acquired":true,"shares":464281,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Reflects a transaction with the Issuer prior to its Section 12 registration which occurred within 6 months of the post-registration transaction reported on this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities II, L.P. (\"BPO-II\"). The general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Ronald M. Hunt, Vijay K. Lathi, Liam T. Ratcliffe and Isaac A. Manke, the managers of BPO Management-II (the \"BPO-II Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":464281,"derivative":{"underlying":"Common Stock","underlying_shares":464281},"source":{"system":"sec-edgar","filing":"0001209191-19-010306","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919119010306/doc4.xml","form_type":"4"}},{"id":3656211,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2019-02-14T17:30:01.000Z","date":"2018-11-09","kind":"purchase","acquired":true,"shares":464281,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"kind","element":"transactionCoding","label":"F6","text":"Reflects a transaction with the Issuer prior to its Section 12 registration which occurred within 6 months of the post-registration transaction reported on this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, a member of the Issuer's board of directors, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-III (the \"NLV-III Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":464281,"derivative":{"underlying":"Common Stock","underlying_shares":464281},"source":{"system":"sec-edgar","filing":"0001209191-19-010306","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919119010306/doc4.xml","form_type":"4"}},{"id":3656210,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-14T17:30:01.000Z","date":"2019-02-12","kind":"purchase","acquired":true,"shares":214285,"price":14,"value":2999990.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities II, L.P. (\"BPO-II\"). The general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Ronald M. Hunt, Vijay K. Lathi, Liam T. Ratcliffe and Isaac A. Manke, the managers of BPO Management-II (the \"BPO-II Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":678566,"source":{"system":"sec-edgar","filing":"0001209191-19-010306","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919119010306/doc4.xml","form_type":"4"}},{"id":3656209,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-14T17:30:01.000Z","date":"2019-02-12","kind":"purchase","acquired":true,"shares":214286,"price":14,"value":3000004.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, a member of the Issuer's board of directors, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-III (the \"NLV-III Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2242839,"source":{"system":"sec-edgar","filing":"0001209191-19-010306","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919119010306/doc4.xml","form_type":"4"}},{"id":3656208,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-14T17:30:01.000Z","date":"2019-02-12","kind":"exercise","acquired":true,"shares":464281,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities II, L.P. (\"BPO-II\"). The general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Ronald M. Hunt, Vijay K. Lathi, Liam T. Ratcliffe and Isaac A. Manke, the managers of BPO Management-II (the \"BPO-II Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the BPO-II Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":464281,"source":{"system":"sec-edgar","filing":"0001209191-19-010306","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919119010306/doc4.xml","form_type":"4"}},{"id":3656207,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-14T17:30:01.000Z","date":"2019-02-12","kind":"exercise","acquired":true,"shares":464281,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, a member of the Issuer's board of directors, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-III (the \"NLV-III Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2028553,"source":{"system":"sec-edgar","filing":"0001209191-19-010306","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919119010306/doc4.xml","form_type":"4"}},{"id":3656206,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-14T17:30:01.000Z","date":"2019-02-12","kind":"exercise","acquired":true,"shares":1564272,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All series of convertible preferred stock automatically converted into shares of the Issuer's common stock on a 1-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of Ronald M. Hunt, a member of the Issuer's board of directors, Vijay K. Lathi, and Liam T. Ratcliffe, the managers of Management-III (the \"NLV-III Managers\"), may each be deemed to have shared voting and investment power with respect to these securities. Each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1564272,"source":{"system":"sec-edgar","filing":"0001209191-19-010306","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919119010306/doc4.xml","form_type":"4"}},{"id":3872452,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Convertible Preferred Stock","published_at":"2018-07-05T16:36:08.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":66694,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into shares of Common Stock, on a one-for-one basis, had no expiration date and converted automatically into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into shares of Common Stock, on a one-for-one basis, had no expiration date and converted automatically into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into shares of Common Stock, on a one-for-one basis, had no expiration date and converted automatically into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are directly beneficially owned by New Leaf Ventures II, L.P. (\"NLV II\"). New Leaf Venture Associates II, L.P. (\"NLV Associates II\") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. (\"NLV Management II\") is the general partner of NLV Associates II. Each of NLV Associates II and NLV Management II may be deemed to have sole voting and investment power with respect to these securities. Each of NLV Associates II and NLV Management II disclaims beneficial ownership of these securities and this report shall not be deemed an admission that either is a beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a member of the Issuer's board of directors, Vijay Lathi and Liam Ratcliffe are the managers of NLV Management II (collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities. Each of the Reporting Person and the other Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is a beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":66694},"source":{"system":"sec-edgar","filing":"0001209191-18-041653","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919118041653/doc4.xml","form_type":"4"}},{"id":3872451,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series F Convertible Preferred Stock","published_at":"2018-07-05T16:36:08.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":421681,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into shares of Common Stock, on a one-for-one basis, had no expiration date and converted automatically into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into shares of Common Stock, on a one-for-one basis, had no expiration date and converted automatically into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into shares of Common Stock, on a one-for-one basis, had no expiration date and converted automatically into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are directly beneficially owned by New Leaf Ventures II, L.P. (\"NLV II\"). New Leaf Venture Associates II, L.P. (\"NLV Associates II\") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. (\"NLV Management II\") is the general partner of NLV Associates II. Each of NLV Associates II and NLV Management II may be deemed to have sole voting and investment power with respect to these securities. Each of NLV Associates II and NLV Management II disclaims beneficial ownership of these securities and this report shall not be deemed an admission that either is a beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a member of the Issuer's board of directors, Vijay Lathi and Liam Ratcliffe are the managers of NLV Management II (collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities. Each of the Reporting Person and the other Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is a beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":421681},"source":{"system":"sec-edgar","filing":"0001209191-18-041653","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919118041653/doc4.xml","form_type":"4"}},{"id":3872450,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Convertible Preferred Stock","published_at":"2018-07-05T16:36:08.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":206380,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into shares of Common Stock, on a one-for-one basis, had no expiration date and converted automatically into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into shares of Common Stock, on a one-for-one basis, had no expiration date and converted automatically into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into shares of Common Stock, on a one-for-one basis, had no expiration date and converted automatically into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are directly beneficially owned by New Leaf Ventures II, L.P. (\"NLV II\"). New Leaf Venture Associates II, L.P. (\"NLV Associates II\") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. (\"NLV Management II\") is the general partner of NLV Associates II. Each of NLV Associates II and NLV Management II may be deemed to have sole voting and investment power with respect to these securities. Each of NLV Associates II and NLV Management II disclaims beneficial ownership of these securities and this report shall not be deemed an admission that either is a beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a member of the Issuer's board of directors, Vijay Lathi and Liam Ratcliffe are the managers of NLV Management II (collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities. Each of the Reporting Person and the other Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is a beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":206380},"source":{"system":"sec-edgar","filing":"0001209191-18-041653","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919118041653/doc4.xml","form_type":"4"}},{"id":3872449,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2018-07-05T16:36:08.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":848360,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into shares of Common Stock, on a one-for-one basis, had no expiration date and converted automatically into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into shares of Common Stock, on a one-for-one basis, had no expiration date and converted automatically into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into shares of Common Stock, on a one-for-one basis, had no expiration date and converted automatically into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are directly beneficially owned by New Leaf Ventures II, L.P. (\"NLV II\"). New Leaf Venture Associates II, L.P. (\"NLV Associates II\") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. (\"NLV Management II\") is the general partner of NLV Associates II. Each of NLV Associates II and NLV Management II may be deemed to have sole voting and investment power with respect to these securities. Each of NLV Associates II and NLV Management II disclaims beneficial ownership of these securities and this report shall not be deemed an admission that either is a beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a member of the Issuer's board of directors, Vijay Lathi and Liam Ratcliffe are the managers of NLV Management II (collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities. Each of the Reporting Person and the other Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is a beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":848360},"source":{"system":"sec-edgar","filing":"0001209191-18-041653","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919118041653/doc4.xml","form_type":"4"}},{"id":3872448,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-05T16:36:08.000Z","date":"2018-07-02","kind":"grant","acquired":true,"shares":8767,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The performance criterion for vesting of this option was met upon the closing of the Issuer's initial public offering.  One twelfth (1/12th) of the shares subject to the option vested or shall vest monthly commencing on March 16, 2018, subject to Reporting Person continuing to provide service through each such date."}],"balance_after":8767,"derivative":{"exercise_price":5.22,"expiration_date":"2028-04-24","underlying":"Common Stock","underlying_shares":8767},"source":{"system":"sec-edgar","filing":"0001209191-18-041653","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919118041653/doc4.xml","form_type":"4"}},{"id":3872447,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":65428,"kind":"person","name":"HUNT RONALD","position":1,"cik":"0001247851","reported_name":"HUNT RONALD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-05T16:36:08.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":66694,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into shares of Common Stock, on a one-for-one basis, had no expiration date and converted automatically into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are directly beneficially owned by New Leaf Ventures II, L.P. (\"NLV II\"). New Leaf Venture Associates II, L.P. (\"NLV Associates II\") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. (\"NLV Management II\") is the general partner of NLV Associates II. Each of NLV Associates II and NLV Management II may be deemed to have sole voting and investment power with respect to these securities. Each of NLV Associates II and NLV Management II disclaims beneficial ownership of these securities and this report shall not be deemed an admission that either is a beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, a member of the Issuer's board of directors, Vijay Lathi and Liam Ratcliffe are the managers of NLV Management II (collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities. Each of the Reporting Person and the other Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is a beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1543115,"source":{"system":"sec-edgar","filing":"0001209191-18-041653","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1247851/000120919118041653/doc4.xml","form_type":"4"}}],"next_cursor":"2018-07-05T16:36:08.000000Z,3872447"}